

**UPDATED NON-CONFIDENTIAL PRESENTATION
TO SUPPORT CEO MEETINGS STARTING MARCH 2019**

Melbourne, Australia, 28 February 2019: Australian drug delivery company, Invion Limited (ASX: IVX) today released an updated non-confidential presentation outlining the clinical strategy for its development of the Photosoft™ technology, and the forward focus of the Company.

The presentation will accompany meetings to be undertaken by Managing Director & CEO, Dr Greg Collier, from March 2019. In addition to a series of business development meetings, Dr Collier will be meeting with brokers, investment bankers and potential investors.

- ENDS -

About Invion

Invion is a drug delivery company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license and distribution rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, The Cho Group, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX).

About Photodynamic Therapy (PDT)

Invion is driving the development of the Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. In contrast to surgery, or radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

Investor enquiries

Managing Director & CEO, Dr Greg Collier

T: +61 3 9081 6005

E: investor@inviongroup.com